Pharma Marketing 2010 - Invest up to 50% less and be among the experts from the industry

North West Business Group30 September 2010, Frankfurt, Germany.
Pharma Marketing 2010 in Frankfurt provides a key platform for Europe's pharmaceutical industry stakeholders, such as yourself, to discover how best to tackle the key challenges of a price-sensitive and increasingly competitive and rapidly changing market.

This event offers the perfect setting for industry peers to present their ideas and successes directly to key decision makers from leading pharmaceutical companies. At this meeting you will meet and interact with senior level marketing executives, through a number of one-on-one meetings and networking activities.

They will discuss the challenges and strategies used to enhance online communication, customer relationship, strengthen brand awareness and improve profitability in marketing. This is your one-stop-shop to the most up to date online marketing strategies, regulatory low down, measuring ROI, analytical tools and more such as:

  • 5 reasons why Pharma should not do E-marketing
  • The successful commercialisation of a pharma brand start with an effective launch
  • Forecasting is easy, communication is difficult
  • Achieving Launch Excellence in a Challenging Pharma Marketplace
  • The Doctor - Patient - Pharma: a triangle about a patient's health improvement.
  • Balancing "old" and "new" marketing strategies
  • Brand Management
  • Why Online Belongs to the Pharma Marketing Mix

Joins some of the experts like:

  • IMS heath, Director commercial effectiveness EMEA
  • UCB Pharma, Head of eStrategies
  • Novartis Oncology Region Europe, Regional Brand Leader
  • Eli Lilly, Director Human Resources
  • Astellas Pharma, Marketing Director
  • Genzyme, Associate Director Global Commercial Effectiveness and Development
  • AstraZneca, VP Global Marketing
  • Allergan, Director Consumer Marketing
  • Google, Industry Head
  • And many more ...

Who should attend?
This conference is designed to attract key decision makers from the Pharmaceutical industry: Presidents, Managing Directors, Country Managers, General Managers, Vice Presidents, Regional Directors/ Heads, Directors, Department Heads, Managers.

For further information and registration, please visit:
http://nwbg.eu/all-events/pharma-marketing-2010/

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...